InvestorsObserver
×
News Home

Where Will Keros Therapeutics Inc (KROS) Stock Go Next After It Has Gained 0.55% in a Week?

Wednesday, June 22, 2022 02:55 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will Keros Therapeutics Inc (KROS) Stock Go Next After It Has Gained 0.55% in a Week?

The market has been neutral on Keros Therapeutics Inc (KROS) stock recently. KROS gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Keros Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on KROS!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With KROS Stock Today?

Keros Therapeutics Inc (KROS) stock is lower by -0.94% while the S&P 500 has gained 0.47% as of 2:55 PM on Wednesday, Jun 22. KROS has fallen -$0.26 from the previous closing price of $27.75 on volume of 191,913 shares. Over the past year the S&P 500 is down -10.47% while KROS has fallen -48.54%. KROS lost -$2.84 per share in the over the last 12 months.

More About Keros Therapeutics Inc

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Click Here to get the full Stock Report for Keros Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App